Summary
Despite the high prevalence of migraine and its health, social, and economic burdens, few effective prophylactic medications have been available. This clinical trial, executed by Iranian research departments, aimed to assess the potential beneficial effects of coenzyme Q10 in migraine prophylaxis. During this trial, 80 patients with migraine headaches received either only their current preventive drugs or their current preventive drugs combined with 100 mg coenzyme Q10 daily. Among others, the frequency and severity of attacks were assessed per month. The number of attacks per month and severity of attacks reduced significantly in the supplementation group. No side effects were observed for coenzyme Q10. More details can be found in the study.
References
Shoeibi et al.